» Articles » PMID: 1321736

The Hepatic Interleukin-6 Receptor. Down-regulation of the Interleukin-6 Binding Subunit (gp80) by Its Ligand

Overview
Journal FEBS Lett
Specialty Biochemistry
Date 1992 Jul 20
PMID 1321736
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin-6 (IL6) exerts its action via a cell surface receptor composed of an 80 kDa IL6-binding protein (gp80) and a 130 kDa polypeptide involved in signal transduction (gp130). We studied the role of gp80 in binding, internalization and down-regulation of the hepatic IL6-receptor (IL6R) by its ligand in human hepatoma cells (HepG2). Comparison of transfected HepG2 cells overexpressing gp80 with parental cells indicate that gp80 is responsible for low affinity binding (Kd = 500 pM) of IL6. Furthermore, gp80 is rate-limiting in internalization and degradation of IL6. Internalization resulted in a rapid down-regulation (t1/2 approximately 15-30 min) of IL6-binding sites at the cell surface. More than 80% of the internalized [125I]rhIL6 was degraded. The reappearance of IL6-binding sites at the cell surface required greater than 8 h and was sensitive to cycloheximide, suggesting that gp80 is not recycled after internalization. The down-regulation of the hepatic IL6R by its ligand might play an important role as a protection against overstimulation.

Citing Articles

Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection.

Lokau J, Garbers Y, Vicente M, Dittrich A, Meltendorf S, Lingel H Front Immunol. 2025; 15():1488745.

PMID: 39835136 PMC: 11743636. DOI: 10.3389/fimmu.2024.1488745.


Unveiling novel insights into human IL-6 - IL-6R interaction sites through 3D computer-guided docking and systematic site mutagenesis.

Li K, Cai J, Jiang Z, Meng Q, Meng Z, Xiao H Sci Rep. 2024; 14(1):18293.

PMID: 39112658 PMC: 11306327. DOI: 10.1038/s41598-024-69429-w.


What do we know about IL-6 in COVID-19 so far?.

Jiang J, Wang J, Yao L, Lai S, Zhang X Biophys Rep. 2023; 7(3):193-206.

PMID: 37287491 PMC: 10244797. DOI: 10.52601/bpr.2021.200024.


IL-6 signalling biomarkers in hospitalised patients with moderate to severe SARS-CoV-2 infection in a single centre study in Sweden.

Ziegler L, Lundstrom A, Havervall S, Thalin C, Gigante B Cytokine. 2022; 159:156020.

PMID: 36057230 PMC: 9420722. DOI: 10.1016/j.cyto.2022.156020.


IL-6 in the Ecosystem of Head and Neck Cancer: Possible Therapeutic Perspectives.

Spanko M, Strnadova K, Pavlicek A, Szabo P, Kodet O, Valach J Int J Mol Sci. 2021; 22(20).

PMID: 34681685 PMC: 8540903. DOI: 10.3390/ijms222011027.